Please login to the form below

Not currently logged in
Email:
Password:

drug rebates

This page shows the latest drug rebates news and features for those working in and with pharma, biotech and healthcare.

US insurers can peg access to ICER value reviews

US insurers can peg access to ICER value reviews

drug prices by pocketing rebates and not passing on savings to customers. ... It insists however this will not be a barrier to drug discovery – as is often cited by drugmakers – as companies currently “spend more on marketing that discovery”.

Latest news

  • Pfizer CEO reckons rebates will disappear, and that’s a positive Pfizer CEO reckons rebates will disappear, and that’s a positive

    Abandoning rebates could deliver a situation where drug prices fluctuate in line with healthcare inflation – and that shouldn’t affect Pfizer’s sales growth predictions, said Read. ... The move also has the support of FDA Commissioner Scott

  • Europe's market access outlook Europe's market access outlook

    G20 Summit in China to continue its campaign for wider international collaboration to control drug prices. ... Details of drug rebates will, in future, be available only to institutions of the German healthcare system that require this information to

  • UK pharma's contribution to NHS hits £1bn mark UK pharma's contribution to NHS hits £1bn mark

    ABPI says local access to new treatments still not universal despite drug rebates. ... The idea is to help make new drug treatments more affordable for the NHS and give UK patients the same level of access to new medicines as other EU countries.

  • The Italian Job The Italian Job

    More rebates are due if Harvard Pilgrim's spending on the drug surpasses an agreed-upon threshold. ... When a country gets rebates totalling 1% of their drug budget, it means that a lot of therapies did not work for a lot of patients.

  • Pfizer settles US Protonix lawsuit for $785m Pfizer settles US Protonix lawsuit for $785m

    US government deal covers Wyeth’s failure to pay drug rebates. After years of legal wrangling, Pfizer has finally agreed to pay $785m to settle a lawsuit claiming its Wyeth unit ... failed to pay rebates due to the US government on gastrointestinal

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    However, if sales in that period exceed 250m, companies will be liable to pay rebates. ... In response to the pharmaceutical industry's concerns about international reference pricing, details of drug rebates will, in future, be available only to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics